NCT02576639 - Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

August 10, 2015

Primary Completion Date

March 11, 2016

Study Completion Date

March 11, 2016

Conditions

Alzheimer's Disease

Interventions

DRUG

CNP520

DRUG

Placebo

Matching placebo to CNP520 was supplied in capsules.

Trial Locations (11)

Novartis Investigative Site, Antwerp

Novartis Investigative Site, Groningen

Novartis Investigative Site, Berlin

Novartis Investigative Site, Miami

Novartis Investigative Site, Lincoln

Novartis Investigative Site, Long Beach

Novartis Investigative Site, Glendale

Novartis Investigative Site, Leiden

Novartis Investigative Site, Belfast

Novartis Investigative Site, Harrow

Novartis Investigative Site, Mid Glamorgan